Background: Due to the infrequency of non-clear cell renal cell carcinoma (RCC), there is currently a paucity of high-quality literature to help guide the effective treatment of these tumors. Recently, biomarkers such as platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), systemic immune inflammation (SII) index and C-reactive protein to albumin ratio (CAR) have been demonstrated to be closely related to poor prognosis of patients with RCC. The objective of this study was to evaluate these biomarkers for determining the progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-clear cell cancer.
Methods: We retrospectively reviewed 31 cases diagnosed with metastatic non-clear cell RCC from January 2012 to December 2017. We assessed the prognostic value (OS and PFS) of pretreatment PLR, LMR, SII index and CAR based on multivariate analysis and Kaplan-Meier survival curve.
Results: Median time of OS and PFS were 15.5 months (95% confidence interval (CI): 13.7 - 15.2) and 10.9 months (95% CI: 8.9 - 12.8), respectively. The median PFS (0.001) and OS (P = 0.01) was shorter in patients with PLR > 171, LMR < 2.61. Moreover, median PFS but not OS was significantly lower in SII index > 883 (P = 0.064) and CAR > 0.11 (P = 0.229). Scan to surgery time (3.91 weeks, P = 0.001) was also significantly related to progression.
Conclusions: Elevated pretreatment inflammatory biomarkers such as PLR, LMR, SII index and CAR are significant determinants of shorter PFS and OS (PLR and LMR only) in patients with metastatic non-clear cell RCC treated with cytoreductive nephrectomy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497011 | PMC |
| http://dx.doi.org/10.14740/wjon1188 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utilizing CT and MRI in Assessing Peritumoral Neovascularization in Renal Cell Carcinoma: A Comprehensive Analysis of Histological Subtypes and Tumor Characteristics by Imaging.
Curr Med Imaging
January 2025
5Department of Radiology, Usak University Teaching and Research Hospital, Usak 64000, Turkey.
Objective: There are variations in prognosis and therapeutic approach for renal cell carcinoma among different histological subtypes. This study aims to determine the relationship between radiologically detected peritumoral neovascularization and the histological subtypes of Renal Cell Carcinoma (RCC) and to assess whether extratumoral neovascularization characteristics detected via imaging can contribute to distinguishing these subtypes alongside tumor size and T-stage.
Materials And Methods: 104 renal tumors from 104 cases consisting of 31 females (29.
Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis.
Front Oncol
December 2024
Department of Oncology, Affliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, China.
Background: Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous group of malignancies with substantial differences in morphology, genetic profiles, clinical behavior, and prognosis. Optimal treatment for nccRCC remains unclear, largely extrapolated from evidence available for clear cell renal cell carcinoma (ccRCC). This study aimed to compare the efficacy of current mainstream drug treatments for nccRCC to provide clinical treatment guidance for advanced cases.
View Article and Find Full Text PDFPost-marketing surveillance data for avelumab + axitinib treatment in patients with advanced renal cell carcinoma in Japan: Subgroup analyses by pathological classification.
Int J Urol
December 2024
Department of Urology, Keio University School of Medicine, Shinjuku-Ku, Tokyo, Japan.
Objective: Clinical trials have demonstrated the efficacy and safety of avelumab + axitinib in patients with advanced clear cell renal cell carcinoma (ccRCC). However, information is limited regarding the activity of avelumab + axitinib in patients with non-clear cell RCC (nccRCC). In Japan, post-marketing surveillance (PMS) of patients with RCC receiving avelumab + axitinib treatment in general clinical practice was undertaken.
View Article and Find Full Text PDFApplication value of contrast-enhanced ultrasound in the preoperative evaluation of renal cell carcinoma histological classification and RENAL score.
Quant Imaging Med Surg
December 2024
Ultrasound Medical Center, Lanzhou University Second Hospital, Lanzhou, China.
Article Synopsis
- Renal cell carcinoma (RCC) is primarily treated through surgical options like radical or partial nephrectomy, and treatment decisions are based on histological classifications and the RENAL score, with contrast-enhanced ultrasound (CEUS) being a safer alternative to traditional imaging methods.
- A retrospective study at Lanzhou University Second Hospital evaluated how CEUS can help in preoperatively assessing RCC histological classifications and RENAL scores by analyzing tumor features in 248 patients undergoing surgery.
- Findings revealed that certain imaging features (hyperenhancement, heterogeneous enhancement, etc.) were significant indicators of clear cell RCC (ccRCC), suggesting CEUS has diagnostic efficacy comparable to contrast-enhanced CT in differentiating between cc
Non-clear cell renal cell carcinoma narrative review: where we are in 2024.
Transl Cancer Res
November 2024
Division of Hematology and Oncology, Department of Internal Medicine, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, USA.
Article Synopsis
- Advances in understanding non-clear cell renal cell carcinoma (RCC) have improved due to better molecular and genetic testing, helping to identify specific subtypes and personalize treatment.
- Representation in clinical trials for rare non-papillary RCC variants is limited, making evidence-based management difficult.
- The shift toward molecular diagnostics is enhancing our knowledge of RCC behaviors and responses to treatments, although most evidence comes from smaller clinical studies rather than extensive trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!